News for OCX Stock

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology Oncocyte Reports Q1 2025 Results and Business Progress Oncocyte to Release First Quarter 2025 Results on May 12, 2025 Oncocyte Provides Positive Update on Clinical Trial Progress Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Oncocyte Prices $29.1 Million Equity Offering Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer Oncocyte Expands Market Opportunity for VitaGraft™ Kidney Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms  Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial Oncocyte Signs Leading Transplant Centers in US and Germany Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results Oncocyte Announces August Investor Conferences Participation Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 Oncocyte Appoints Andrea James as Chief Financial Officer Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine Oncocyte Reports First Quarter 2024 Financial Results Oncocyte to Announce First Quarter 2024 Financial Results Oncocyte Reports Full Year 2023 Financial Results Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results Oncocyte to Present at the Sequire Investor Summit in Puerto Rico Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays Oncocyte Reports Third Quarter 2023 Financial Results Oncocyte to Announce Third Quarter 2023 Financial Results Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage Oncocyte Reports Second Quarter 2023 Financial Results Oncocyte Regains Compliance With Nasdaq Listing Requirements Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference Oncocyte To Announce Second Quarter 2023 Financial Results VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients Oncocyte Announces 1-For-20 Reverse Stock Split Oncocyte Begins Manufacturing Transplant Blood Test Oncocyte Corporation to Present at the LD Micro Invitational XIII Oncocyte Reports First Quarter 2023 Financial Results Oncocyte To Announce First Quarter 2023 Financial Results Oncocyte Presents New Data at AACR Oncocyte Announces Reduction in Force Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer Oncocyte Pricing of $13.86 Million Public Offering of Common Stock Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer Oncocyte Completes Razor Genomics Transaction Oncocyte Announces Initiatives to Focus Corporate Strategy Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors Oncocyte Announces Executive Leadership Changes Oncocyte Reports Third Quarter 2022 Financial Results Oncocyte to Announce Third Quarter 2022 Financial Results DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference Oncocyte Announces Five-Year VA Contract for DetermaRx Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer Oncocyte Reports Second Quarter 2022 Financial Results Oncocyte to Participate at Upcoming Investor Conferences Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 Oncocyte to Announce Second Quarter 2022 Financial Results Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy Oncocyte Reports First Quarter 2022 Financial Results Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test Oncocyte to Announce First Quarter 2022 Financial Results Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™ Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022 Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China Oncocyte Corporation Hosting Business Update Call Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Oncocyte Hosting Two-Part Key Opinion Leader Event Series Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare Oncocyte to Present New Data on DetermaIO™ from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021 Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update Oncocyte to Participate in Upcoming Investor Events Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10 Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc. Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17 Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™ Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types Oncocyte To Present New Data at 2021 American Association for Cancer Research (AACR) Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™ Oncocyte Announces Formation of Medical Advisory Board Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx™ Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16 Oncocyte Closes Second Investment In Razor Genomics to Complete Acquisition Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021 Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Oncocyte Announces Closing of $40 Million Public Offering of Common Stock Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock Oncocyte Announces Proposed Public Offering of Common Stock Oncocyte to Present New Data at the IASLC 2020 World Conference on Lung Cancer Oncocyte Announces $25 Million Registered Offering Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference Oncocyte to Present at the 15th Annual LD Micro Main Event Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference Oncocyte Presents New Data on Its DetermaIO™ Test at Association for Molecular Pathology (AMP) 2020 Conference Oncocyte Reports Third Quarter 2020 Financial Results and Provides Corporate Update Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) Conference Oncocyte to Report Third Quarter 2020 Financial Results on Thursday, November 12 Oncocyte Named One of the 2020 Best Places to Work in Orange County in Its First Year in Irvine, CA Oncocyte Announces Third Quarter Growth of DetermaRx™ Physician Adoption and Testing Volume Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival Oncocyte and Fondazione Michelangelo, a Leading Non-Profit Cancer Research Foundation, Announce Immune Therapy Biomarker Collaboration Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services Oncocyte to Present at the LD 500 Virtual Conference Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference Oncocyte Provides Corporate Update and Reports Second Quarter 2020 Financial Results Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29 Oncocyte Announces Completion of DetermaDx™ Clinical Validation Study Oncocyte Announces New Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrating That the DetermaIO™ Gene Expression Test May Predict Response to Immunotherapy in Triple Negative Breast Cancer Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx™ and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx™ Oncocyte to Hold KOL Webinar Showcasing New Data and Real World Usage of DetermaRx™ Oncocyte Announces Final Local Coverage Determination from Noridian Healthcare Solutions for DetermaRx™, Securing National Medicare Payment for the Test Starting August 2020 Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ Reimbursements Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial Results Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx™